Detalles de la búsqueda
1.
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Hematol Oncol
; 40(2): 269-279, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35043428
2.
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Hematol Oncol
; 37(4): 464-473, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31251400
3.
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Br J Clin Pharmacol
; 83(3): 527-539, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27662429
4.
Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models.
CPT Pharmacometrics Syst Pharmacol
; 13(1): 41-53, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37843389
5.
Population Pharmacokinetic and Exposure-Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis.
Clin Pharmacol Ther
; 2024 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38863178
6.
Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials.
J Clin Pharmacol
; 63(8): 950-960, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37055934
7.
Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.
Clin Pharmacokinet
; 62(4): 623-634, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36905528
8.
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ Perspective.
Clin Pharmacol Ther
; 114(2): 266-274, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36802040
9.
Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial.
J Clin Pharmacol
; 62(10): 1236-1246, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35403245
10.
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet.
Clin Drug Investig
; 42(8): 657-668, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35829925
11.
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
J Clin Pharmacol
; 61(9): 1195-1205, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33894017
12.
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Clin Pharmacol Ther
; 109(2): 424-432, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32749675
13.
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Clin Transl Sci
; 14(1): 277-287, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32770720
14.
Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
J Clin Pharmacol
; 60(3): 331-339, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31515816
15.
Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.
Clin Transl Sci
; 12(6): 625-632, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31268229
16.
Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
Cancer Chemother Pharmacol
; 84(5): 977-986, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31468137
17.
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
J Clin Pharmacol
; 59(9): 1225-1235, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30990907
18.
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.
Clin Pharmacokinet
; 57(11): 1407-1419, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29516428
19.
Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
Leuk Lymphoma
; 59(4): 871-879, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28797193
20.
Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies.
Hemasphere
; 7(12): e983, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38026788